Figure 10.
The in vivo anti-tumor efficacy was studied using a xenograft tumor model in nude mice by subcutaneous implantation of U87DR cells. The mice were divided into 3 groups and subject to intravenous injection of 100 μL of PBS (control), LipCP (7 mg/mL) or ImmuLipCP (7 mg/mL) on day 6, 8, 10 and 12. (A) The gross view of tumors retrieved on day 14. (B) The efficacy of treatment was evaluated from change of tumor size with time (n = 5). * p < 0.05, LipCP vs control; # p < 0.05 ImmuLipCP vs control; & p < 0.05 ImmuLipCP vs LipCP. (C) The change of body weight with time (n = 5). (D) The survival curve as obtained from the survival time of mice by sacrificing the animal when the tumor volume exceeds 1000 mm3 (n = 5).